Radiopharmaceuticals Face Dosimetry and Safety Gaps

Different emitters, different development problems

The abstract, dated May 1, 2026, reviews developments involving alpha- and beta-emitting radiopharmaceuticals, including actinium-225, lutetium-177, iodine-131 and radium-223. Its clinically relevant message is not that one emitter class is more effective. It is that radiation range, energy deposition, biodistribution, isotope production and follow-up requirements shape each product’s development program.

Alpha particles deposit high energy over a short path. That can be attractive for killing targeted tumor cells while limiting irradiation beyond the immediate microenvironment, but it makes microscopic distribution especially important. An organ-level absorbed-dose estimate may conceal large differences among tumor cells, normal tissue compartments and emitted daughter radionuclides.

Beta particles generally travel farther in tissue, creating a cross-fire effect that can irradiate neighboring cells even when target expression or delivery is uneven. That may reduce dependence on perfect cell-level targeting, but it also exposes a broader tissue volume. Quantitative imaging is often more feasible for beta-emitting products with imageable emissions, although scanner calibration, imaging schedules and kinetic modeling remain sources of variation.

These differences are mechanistic and operational. They do not establish comparative clinical effectiveness. The products have been studied in different malignancies, disease stages, combinations and endpoints, so comparing response rates or survival results across programs would be misleading.

What the supporting trials do—and do not—show

The conference report is a review abstract rather than a randomized comparison. It does not describe a single study population, sample size, comparator, effect estimate or follow-up period. Separate phase 3 trials provide clinical context for individual agents, but they cannot answer whether alpha therapy is superior to beta therapy.

In VISION, 831 patients with previously treated, prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer were randomized to lutetium-177 vipivotide tetraxetan plus protocol-permitted standard care or standard care alone. At a median follow-up of 20.9 months, median imaging-based progression-free survival was 8.7 versus 3.4 months, with a hazard ratio of 0.40 and a 99.2% confidence interval of 0.29 to 0.57. Median overall survival was 15.3 versus 11.3 months, with a hazard ratio of 0.62 and a 95% confidence interval of 0.52 to 0.74.

NETTER-1 randomized 229 patients with advanced, progressive, somatostatin receptor–positive midgut neuroendocrine tumors to lutetium-177 dotatate plus long-acting octreotide or high-dose long-acting octreotide. At the prespecified interim analysis, estimated progression-free survival at 20 months was 65.2% versus 10.8%; the hazard ratio for progression or death was 0.21, with a 95% confidence interval of 0.13 to 0.33.

ALSYMPCA evaluated the alpha emitter radium-223 in 921 patients with symptomatic castration-resistant prostate cancer and bone metastases but no known visceral metastases. Radium-223 improved median overall survival to 14.9 months from 11.3 months with placebo; the hazard ratio was 0.70, with a 95% confidence interval of 0.58 to 0.83.

Those results established benefits within specific populations and treatment pathways. They are not suitable for cross-trial ranking because the molecular targets, metastatic patterns, control groups and outcome assessments differed. Actinium-225 programs are earlier in development, while iodine-131 occupies a mature but disease-specific role built over decades rather than through one modern platform trial.

Why dosimetry and supply affect clinical translation

Administered activity is not the same as absorbed dose. The dose reaching a tumor or organ depends on uptake, clearance, physical decay, tumor size and tissue geometry. For actinium-225, the decay chain adds another issue: daughter radionuclides can separate from the targeting molecule and redistribute. A mean organ dose may therefore incompletely represent cell-level exposure and toxicity.

Lutetium-177 can be followed with imaging, supporting serial estimates of tumor, kidney and marrow exposure. Even so, centers may use different acquisition times, reconstruction methods, calibration standards and dose models. Standardization matters both for multicenter trials and for determining whether individualized dosimetry improves outcomes over fixed-activity approaches.

Supply is also part of the evidence problem. Actinium-225 remains constrained by limited production and by differences among production routes, purification processes and impurity profiles. Lutetium-177 has a more developed production network, but expanding indications could pressure reactor, processing and distribution capacity. Iodine-131 benefits from mature infrastructure, although volatility, radiation-protection requirements and radioactive-waste handling remain operational concerns.

Radium-223 likewise requires specialized manufacturing and time-sensitive distribution.

For policymakers and trial sponsors, reliable production is not merely a commercial consideration. Interrupted or uneven supply can delay enrollment, reduce geographic access and make protocols harder to reproduce. Manufacturing changes may also require evidence that radionuclidic purity, specific activity and product performance remain comparable.

The uncertainties that require longer follow-up

Late marrow injury, kidney effects and secondary malignancies may emerge well after conventional oncology trial follow-up. The concern differs by agent and biodistribution: marrow exposure is especially relevant for bone-seeking products and patients with extensive skeletal disease, while renal exposure is important for agents cleared through the kidneys. Prior chemotherapy, external-beam radiation and earlier radionuclide therapy can complicate attribution.

The main limitation is the evidence format. A conference review abstract cannot provide the methodological detail of a systematic review, and it does not report a pooled population, prespecified search strategy, comparative effect estimate or formal assessment of bias. Generalizability, funding and conflicts should be evaluated from the full presentation and disclosures when available.

The evidence supports building development programs around each isotope’s pharmacology, production route and target population. It also supports common dosimetry standards, transparent manufacturing specifications and longitudinal safety registries. It does not support choosing an alpha or beta emitter solely from its particle type or from indirect comparisons among unrelated trials.

Questions clinicians ask

Does an alpha emitter necessarily deliver better tumor control than a beta emitter?

No. Alpha particles have higher linear energy transfer and a shorter tissue range, but clinical benefit also depends on target expression, tumor penetration, retention and normal-tissue exposure. No head-to-head evidence in this review establishes that alpha-emitting products outperform beta-emitting products across cancers.

Is patient-specific dosimetry ready to determine every treatment course?

Not uniformly. Quantitative imaging can estimate organ and tumor exposure for some products, particularly lutetium-177 agents, but acquisition methods and dose models vary. Evidence is still needed to show when individualized dosimetry improves outcomes compared with established fixed-activity regimens.

Why is actinium-225 supply a clinical-development issue?

Limited isotope availability can restrict enrollment, site participation and eventual access. Different production methods may also generate different impurity profiles or quality-control requirements, meaning that expanded capacity must be accompanied by validated manufacturing, purification and release standards.

What follow-up is needed after radiopharmaceutical therapy?

Follow-up should reflect the agent’s known biodistribution and the patient’s prior treatment exposures. Trials and registries need enough duration to characterize persistent cytopenias, renal effects and secondary malignancies, because these outcomes may be missed by response-focused studies with relatively short observation periods.

References

1. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer — The New England Journal of Medicine, 2021
2. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors — The New England Journal of Medicine, 2017
3. Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer — The New England Journal of Medicine, 2013